Psilocybin-Assisted Psychotherapy for Veterans With PTSD

Posttraumatic stress disorder (PTSD) is a severe and debilitating mental health conditionthat significantly impacts patients' lives, leading to functional impairments, strainedrelationships, and high healthcare costs. About half of the patients with PTSD do notbenefit from current evidence‐based psychotherapy and available pharmacologicaltreatments offer only limited benefits. Therefore, there is a high need for noveltherapeutic approaches in the treatment of PTSD.Psilocybin‐assisted psychotherapy is a promising approach combining the pharmacologicaleffects of psilocybin, a serotonergic psychedelic, with psychotherapy.Psilocybin‐assisted psychotherapy has shown promising effects in several phase 2 studiesin the treatment of mental health conditions such as depression and end‐of‐life anxiety,with two phase 3 studies underway for treatment‐resistant depression. Building on theseinitial promising results, psilocybin‐assisted psychotherapy is increasingly beingstudied for other psychiatric indications, including PTSD.Many of psilocybin's potential therapeutic mechanisms appear to be transdiagnostic innature. For example, studies suggest that psilocybin can enhance introspection, emotionalprocessing, and psychological flexibility, all of which could facilitatepsychotherapeutic processes. Psilocybin has also been shown to reduce avoidance andpromote neural plasticity and cognitive reappraisal, which could be particularly relevantfor addressing core symptoms of PTSD, such as persistent avoidance and rigid negativethought patterns. Furthermore, its ability to foster a sense of connectedness aligns wellwith the therapeutic need of individuals with PTSD who face challenges related to socialisolation.Preliminary findings from an initial Phase 2 trial suggest that psilocybin‐assistedpsychotherapy may be safe and associated with clinically meaningful improvements in PTSDsymptoms. However, this study differed from the present study in several importantaspects. Participants were not required to have had previous unsuccessful evidence‐basedpsychotherapies for PTSD, and psilocybin administration was not embedded withinpsychotherapeutic treatment. The current open‐label pilot study will focus on veteranswith treatment‐refractory PTSD, a patient population that frequently shows partial or noresponse to standard evidence‐based PTSD treatment. In addition, psilocybinadministration will be part of an extensive psychotherapeutic treatment protocol. Thisstudy aims to collect data on the feasibility, preliminary efficacy and safety ofpsilocybin‐assisted psychotherapy in this population, to inform a potential futurerandomized controlled trial.